Literature DB >> 34907544

A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014.

Anders Forss1,2, Mark Clements1, David Bergman1, Bjorn Roelstraete1, Gilaad G Kaplan3, Pär Myrelid4, Jonas Halfvarson5, Ola Olén1,6, Jonas F Ludvigsson1,7,8.   

Abstract

BACKGROUND: Epidemiological studies have shown inconsistent incidence rates (IRs) for inflammatory bowel disease (IBD). AIM: To assess the incidence and temporal trends of IBD in Sweden.
METHODS: Nationwide cohort study based on diagnostic codes for IBD and biopsy reports registered through the ESPRESSO cohort in 1990-2014. Age-specific and age-standardised IRs and cumulative incidence were calculated.
RESULTS: Overall, we identified 65 908 cases of incident IBD: ulcerative colitis (UC, n = 38 261, 58%), Crohn's disease (CD, n = 18 577, 28%) and IBD-U (n = 9070, 14%). During 1990-2014, the overall IRs per 100 000 person-years were 29.0 (95% CI: 27.3-30.7) for IBD, 16.9 (15.9-17.9) for UC, and 8.1 (7.7-8.6) for CD. For IBD-U, the IR was 5.2 (4.9-5.6) in 2002-2014. The annual incidence of IBD, UC and CD increased by approximately 7% per year between 1990 and 2001 (P < 0.001) and then decreased by 1%-2% per year from 2002 onwards (P < 0.001). IRs for IBD, UC and IBD-U were higher in males while the IR for CD was higher in females. The lifetime risk of IBD was about 2.5% for both sexes.
CONCLUSIONS: In Sweden, the incidence of IBD in all subtypes increased in 1990-2001 but has since declined. One in 40 individuals is expected to be diagnosed with IBD during their lifetime.
© 2021 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2021        PMID: 34907544     DOI: 10.1111/apt.16735

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  2 in total

1.  Adherence to and Persistence with Adalimumab Therapy among Swedish Patients with Crohn's Disease.

Authors:  Yifei Liu; Joakim Söderberg; Jingdong Chao
Journal:  Pharmacy (Basel)       Date:  2022-07-20

2.  Mortality and cancer in eosinophilic gastrointestinal disorders distal to the esophagus: nationwide cohort study 1990-2017.

Authors:  Adam C Bledsoe; John J Garber; Weimin Ye; Bjorn Roelstraete; Joseph A Murray; Jonas F Ludvigsson
Journal:  J Gastroenterol       Date:  2022-07-19       Impact factor: 6.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.